RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic <i>BRCA</i> mutation.
Susan M. Domchek(University City Science Center), Rachna T. Shroff(University of Arizona), Steven R. Alberts(North Central Cancer Treatment Group), Andrew Hendifar(Cedars-Sinai Medical Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Robert H. Vonderheide(University of Pennsylvania), Ravit Geva(Tel Aviv Sourasky Medical Center), Kevin Lin(The University of Texas MD Anderson Cancer Center), Ron Epelbaum(University of Bern), Andrew V. Biankin(University of Glasgow), Robert R. McWilliams(Mayo Clinic in Arizona), Sandra Goble(Clovis Oncology (United States)), Heidi Giordano(Mayo Clinic in Arizona)
Cited by 27
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k